Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acceptance and commitment therapy group protocol for caregivers of anxious youth: an open trial pilot study.
Front Child Adolesc Psychiatry
September 2024
Department of Psychiatry, University of Massachusetts Chan Medical School, Worcester, MA, United States.
Introduction: Anxiety disorders are common, distressing, and impairing for children and families. Cognitive-behavioral interventions targeting the role of family interactions in child anxiety treatment may be limited by lack of attention to antecedents to parental control; specifically, internal parent factors such as experiential avoidance and cognitive fusion. This pilot study evaluates the preliminary efficacy of a group-delivered caregiver treatment program, ACT for Parents of Anxious Children (ACT-PAC) that targets parental experiential avoidance, cognitive fusion, and child internalizing symptoms.
View Article and Find Full Text PDFProbing the Neurodynamic Mechanisms of Cognitive Flexibility in Depressed Individuals with Autism Spectrum Disorder.
J Child Adolesc Psychopharmacol
January 2025
Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Autism spectrum disorder (ASD) is characterized by deficits in social behavior and executive function (EF), particularly in cognitive flexibility. Whether transcranial magnetic stimulation (TMS) can improve cognitive outcomes in patients with ASD remains an open question. We examined the acute effects of prefrontal TMS on cortical excitability and fluid cognition in individuals with ASD who underwent TMS for refractory major depression.
View Article and Find Full Text PDFVitamin D and COVID-19: comparative analysis with other respiratory infections and impact of comorbidities.
Germs
September 2024
Pharm, PhD, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, No. 6 Traian Vuia street, Bucharest, 020956, Romania.
Introduction: The COVID-19 pandemic has promoted an intensive investigation into the pathophysiological mechanisms of SARS-CoV-2 infection, risk factors, and its impact on disease severity. Vitamin D has generated significant attention for its potential role in viral prevention and immune defense due to its pleiotropic functions, including immunomodulation and antimicrobial effects. This study aimed to assess serum 25(OH)D3 levels in patients with COVID-19 compared to those with other viral respiratory infections and to evaluate associations of vitamin D levels with symptomatology, clinical characteristics, presence of comorbidities and laboratory investigation.
View Article and Find Full Text PDFManaging cognitive impairment in Parkinson's disease: an update of the literature.
Expert Rev Neurother
January 2025
Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Introduction: Cognitive impairment in Parkinson's disease (PD) substantially affects patient outcomes, function, and quality of life. PD-related cognitive dysfunction is often heterogeneous in clinical presentation and rates of progression. As cognitive changes occur in many people with PD, it is essential to evaluate cognition, provide education, and implement management strategies for cognitive symptoms.
View Article and Find Full Text PDFEfficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.
Neurol Ther
January 2025
Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.
Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!